Tianjin Children's Hospital
16
4
4
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
6.3%
1 terminated/withdrawn out of 16 trials
0.0%
-86.5% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome
Role: collaborator
Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China
Role: collaborator
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
Role: collaborator
Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease
Role: collaborator
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
Role: collaborator
Belimumab After Rituximab in Resistant Primary Juvenile SS
Role: collaborator
Registry of IgA Nephropathy in Chinese Children
Role: collaborator
The CMCPCTH Research in Chinese Children
Role: collaborator
the Effects of Air Pollution on Respiratory Diseases in Children
Role: collaborator
Analysis of Risk Factors for Children With Heterochronous Indirect Hernia
Role: collaborator
Fabry Aim Children Early (ACE) Project
Role: collaborator
Clinical Feature and Microbiology Characteristics of Empyema in Children
Role: collaborator
Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
Role: collaborator
Mycoplasma Infection Rate and Macrolides Resistance in Children With Acute Respiratory Tract Infection
Role: collaborator
Aetiology of Children With Bronchiectasis in China
Role: collaborator
Prognosis of Bronchiectasis in Children--A Multicenter Prospective Cohort Study
Role: collaborator
All 16 trials loaded